Juniper Investment Company, LLC (Bartholdson John A., MICHAS ALEXIS P) sold $2.7M of OFIX (indirect holdings)

Juniper Investment Company, LLC sold 310,000 indirectly-held shares of Orthofix Medical Inc. (OFIX) at an average of $8.81 ($8.74–$8.86, $2.73M total) across 2 trades over 2026-09-18 to 2026-09-21. Filed jointly with Bartholdson John A. (10% owner) and MICHAS ALEXIS P (10% owner).

Original reporting
SEC EDGAR · Juniper Investment Company, LLC, Bartholdson John A., MICHAS ALEXIS P
Published Sep 22, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OFIX
Bearish
medium confidence
Mentioned
$OFIX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OFIXBearishMed
01

Why it matters

The disclosed sale reduces a major insider's stake, which may be interpreted as a lack of confidence, influencing short‑term price action.

02

Market read

Primary insider sale provides fresh material for traders assessing OFIX's near‑term risk.

03

What to watch

Potential upcoming FDA decisions or clinical trial news could offset the negative signal from the insider sale.

Relevance 6/10Novelty 8/10Timing: filing date 2026-09-22

Background

Form 4 filing reveals insider transaction details for Orthofix Medical Inc. (OFIX).

Company-level read

Ticker impact

$OFIXBearishMedium confidence
Context

Juniper Investment Company, LLC sold $2.7M of OFIX shares, reducing its indirect stake to 3.77M shares.

Expected impact

Possible short-term downside pressure; price may dip 2‑4% on the news.

Evidence & confidence

The sale size ($2.7M) is material for a mid‑cap biotech and the insider holds a significant stake, making the transaction noteworthy for traders.

Market effects

May raise concerns for the medical device sector if other insiders follow suit.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact; primarily relevant to OFIX shareholders.

Counterpoint

The sale could be a portfolio rebalancing unrelated to company fundamentals; price may remain stable.

Key entities

  • Orthofix Medical Inc.

    Medical device manufacturer listed on NASDAQ under OFIX.

  • Juniper Investment Company, LLC

    Investment vehicle holding a 10% indirect stake in OFIX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OFIXHighAI 8/10

Orthofix Earnings Call Shows Growth Amid Spine Challenges

Orthofix Medical reported Q3 revenue of $207.9M, up 2.3% YoY. Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively, while U.S. Spine declined 5%. Adjusted EBITDA improved to $26M. Management lowered 2026 guidance, citing Spine market softness and supply issues, but expects 2027 core revenue growth excluding MDR impact.

Med

Orthofix Medical Inc. Q3 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q3 2026 earnings below expectations due to U.S. Spine market softness and supplier delays. The company is consolidating distributors, with core partners generating 80% of U.S. spinal implant revenue. Updated full-year 2026 revenue guidance is $825M-$830M. Management expects a $22M net sales headwind in 2027 due to European MDR requirements. The VIRATA spinal implant system is set for full market launch in late Q4 2026.

$OFIXMedAI 8/10

Orthofix Medical (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical (OFIX) reported Q3 2026 net sales of $207.9M, up 2.3% YoY. Spine sales fell 1%, while Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively. The company is focusing on strategic partnerships, simplifying its product portfolio, and aligning costs. It expects near-term sales pressure due to these transitions and updated guidance accordingly. Cash reserves stood at $86.9M.

$OFIXMed

Orthofix 3Q 2026: Revenue $207.86M, EPS ($0.15) — 10-Q Summary

Orthofix reported 3Q 2026 revenue of $207.86M, up 1.1% YoY, with a net loss of $6.07M, improved from $22.8M last year. Therapeutic Solutions and Global Limb Reconstruction sales grew, while Spinal Implants and other segments declined. Gross margin fell to 70.5% due to product mix changes. SG&A expenses decreased by $22.8M, driven by lower legal costs and commissions.

$OFIXMed

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Orthofix Medical Inc. (OFIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarte